Skip to main content
SpringerLink
Log in

The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks

  • Hypertension
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

The data on treatment of hypertension in black patients with beta-adrenoceptor blockers (BB) or calcium-entry blockers (CEB) have been reviewed. There is much evidence that in monotherapy BB are no better than inert placebo for the majority of hypertensive black patients. Their hypotensive action in blacks is less than that induced by other antihypertensive agents, mainly diuretics. Comparative evaluation of the responsiveness of blacks, whites, and Indians to BB therapy showed a poorer control of blood pressure (BP) among blacks than among nonblacks. However, when combined with diuretic therapy, BBs are equipotent in blacks and whites. The reasons for the hyporesponsiveness of black patients to BB therapy are not fully understood. On the other hand, CEBs appear to be as efficacious as diuretic therapy in hypertensive blacks. In addition, they lower blood pressure to the same extent in black and white patients. They are also proven to be effective adjunctive therapy to diuretics for hypertension in blacks. The reason for the better responsiveness of blacks to CEB therapy might include the severity of hypertension in blacks, their low plasma renin, their blunted sympathetic activity, and their high intracellular sodium concentration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response.JAMA 1982;248:1996–2003.

    Article  Google Scholar 

  2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension.Am J Cardiol 1983;52:1230–1237.

    Article  Google Scholar 

  3. Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black patients with hypertension.Clin Pharmacol Ther 1982;32:307–312.

    Article  PubMed  CAS  Google Scholar 

  4. Parrish EF, Hall WD, Wollam GL, et al. Hemodynamic and plasma volume measurements in 47 hypertensive blacks (abstract).Clin Res 1983;31:844A.

    Google Scholar 

  5. Chrysant SG, Danisa K, Kem DC, et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension.Hypertension 1979;1:136–141.

    PubMed  CAS  Google Scholar 

  6. Freis ED, Naterson BJ, Flamenbaum W. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system.Am J Med 1983;74:1022–1041.

    Article  Google Scholar 

  7. Holland OB, Fairchild C, Gomez-Sanchez C, Kaplan NM. Comparison of aldactazide and dyazide for hypertension.Curr Ther Res 1977;22:479–489.

    CAS  Google Scholar 

  8. Woods JW, Pittman AW, Pulliam CC, et al. Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.N Engl J Med 1976;294:1137–1143.

    Article  PubMed  CAS  Google Scholar 

  9. Holland OB, Gomez-Sanchez C, Fairchild C, Kaplan NM. Role of renin classification for diuretic treatment of black hypertensive patients.Arch Intern Med 1979;139:1365–1370.

    Article  PubMed  CAS  Google Scholar 

  10. Holland OB, Fairchild C. Renin classification for diuretic and beta-blocker treatment of black hypertensive patients.J Chronic Dis 1982;35:179–182.

    Article  PubMed  CAS  Google Scholar 

  11. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group.JAMA 1982;248:1465–1477.

    Article  Google Scholar 

  12. Holme I, Helgeland A, Hjermann I, et al. Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo study and MRFIT.JAMA 1984; 251:1298–1299.

    Article  PubMed  CAS  Google Scholar 

  13. Walker WG, Hermann J, Russell RP. The risk of diuretic usage in hypertensive black diabetics (abstract). In:3rd International Interdisciplinary Conference on Hypertension in Blacks, April 21–23, 1988, Baltimore.

  14. Humphreys GS, Delvin DG. Ineffectiveness of propranolol in hypertensive Jamaicans.Br Med J 1968;2:601–603.

    PubMed  CAS  Google Scholar 

  15. Seedat YK, Reddy R. Propranolol in the South African nonwhite hypertensive patients.S Afr Med J 1971;45:284–285.

    PubMed  CAS  Google Scholar 

  16. Seedat YK. Trial of atenolol and chlorthalidone in black South Africans.Br Med J 1980;281:1241–1243.

    PubMed  CAS  Google Scholar 

  17. Obel AO, Gitan W. Comparison of the antihypertensive effect of metipranolol butizide and Torrat in Kenyan Africans.East Afr Med J 1982;58:867–871.

    Google Scholar 

  18. Odia OJ, Cole TO. Evaluation of a single daily dose of acebutolol 400 mg in the treatment of Nigerian hypertensives.Curr Ther Res 1986;40:680–684.

    Google Scholar 

  19. Grell GAC, Forrester T. Is a beta-blocker as effective as a diuretic in the management of black hypertensives? In:National Conference on High Blood Pressure Control. Unresolved Issues: New Approaches. April 28–30, 1985, Chicago, Illinois.

  20. Grell GAC, Forrester TE, Allegne, GAO. Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthalidone) in black hypertensive patients.S Afr Med J 1984;77:1524–1529.

    CAS  Google Scholar 

  21. Moser M, Lum J. Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients.Angiology 1982;32:561–566.

    Google Scholar 

  22. Richardson DW, Freund J, Gear MS, Mauck HP, Preston LW. Effect of propranolol on elevated blood pressure.Circulation 1968;37:534–535.

    PubMed  CAS  Google Scholar 

  23. Veterans Administration Cooperative Study on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy.JAMA 1982;248:2004–2237.

    Article  Google Scholar 

  24. Flamenbaum W, Weber MA, McMahon FG, et al. Monotherapy with labetolol compared with propranolol. Differential effects by race.J Clin Hypertens 1985;1:56–69.

    PubMed  CAS  Google Scholar 

  25. El Ackad TN, Curry CL, Hinds JE, et al. Comparison of the antihypertensive efficacy of labetolol with that of propranolol in black hypertensive patients (abstract).Clin Res 1984;32:330A.

    Google Scholar 

  26. Cubberly RB. Labetolol as monotherapy in hypertensive black patients.J Clin Hypertens 1985;1:304–314.

    Google Scholar 

  27. Hamilton J, Kuzbida G, Pavlis R, Hamilton B. Low dose clonidine versus propranolol in elderly predominantly black mild to moderate hypertensives. In:3rd International Interdisciplinary Conference on Hypertension in Blacks, April 21–23, 1988, Baltimore.

  28. Seedat YK. Current status of beta-blockers in black hypertensive patients (editorial).S Afr Med J 1987;72:169–170.

    PubMed  CAS  Google Scholar 

  29. Salako LA, Falase AO, Ragon A, Adio RA. Beta-adrenoceptor blocking effects and pharmacokinetics of pindolol. A study in hypertensive Africans.Eur J Clin Pharmacol 1979;15:299.

    Article  PubMed  CAS  Google Scholar 

  30. Salako LA, Falase AO, Aderounmu AF. Comparative β-adrenoceptor blocking effects and pharmacokinetics of propranolol and pindolol in hypertensive Africans.Clin Sci 1979;57(Suppl):393s-396s.

    PubMed  Google Scholar 

  31. Warren SE, O'Connor DT. Does a renal vasodilator system mediate racial differences in essential hypertension?Am J Med 1980;69:425–429.

    Article  PubMed  CAS  Google Scholar 

  32. Aderounmu AF, Salako LA, Falase AO. TheAntihypertensive effect of pindolol (Visken) alone and in combination with clopamide (Viskaldix) in Africans.Curr Ther Res 1981; 29:379–382.

    Google Scholar 

  33. O'Brien ET, McKinnon J. Propranolol and polythiazide in treatment of hypertension.Br Heart J 1972;34:1042–1044.

    PubMed  Google Scholar 

  34. Obel AO. A comparison of timolol plus hydrochlorothiazide plus amibride and methyldopa in esential hypertension in black Africans.Trop Geogr Med 1983;35:285–292.

    PubMed  CAS  Google Scholar 

  35. M'Buyamba-Kabangu JR, Fagard R, Lijnen P, et al. Calcium entry blockade or beta-blockade in long-term management of hypertension in blacks.Clin Pharmacol Ther 1987;41:45–54.

    Article  PubMed  Google Scholar 

  36. Venker CP, Joubert PH. Penbutolol in black hypertensive patients.S Afr Med J 1986;69:286–287.

    Google Scholar 

  37. Fadayomi MO, Akinroye KK, Ajao RO, Awosvka LA. Monotherapy with nifedipine for essential hypertension in adult blacks.J Cardiovasc Pharmacol 1986;8:466–469.

    Article  PubMed  CAS  Google Scholar 

  38. Dustan HP. Nitrendipine in black US patients.J Cardiovasc Pharmacol 1987;9(Suppl):267s-271s.

    Google Scholar 

  39. McAllister E, Affinito E, Dickson B. Response to sustainedrelease verapamil HCl in hypertensive black patients with stable cardiac disease. In:3rd International Interdisciplinary Conference on Hypertension in Blacks, April 21–23, 1988, Baltimore.

  40. Moser M, Lunn J, Materson BJ. Comparative effects of diltiazem and hydrochlorothiazide in blacks with systemic hypertension.Am J Cardiol 1985;56:101H-104H.

    Article  PubMed  CAS  Google Scholar 

  41. M'Buyamba-Kabangu JR, Lepira B, Lijnen P, et al. Intracellular sodium and the response to nitrendipine or atenolol in African blacks.Hypertension 1988;11:100–105.

    PubMed  Google Scholar 

  42. Cubeddu LX, Aranda J, Singh B, et al. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response.JAMA 1986; 256:2214–2221.

    Article  PubMed  CAS  Google Scholar 

  43. Isles CG, Johnson AO, Milne FJ. Slow-release nifedipine and atenolol as initial treatment in blacks with malignant hypertension.Br J Clin Pharmacol 1986;21:377–383.

    PubMed  CAS  Google Scholar 

  44. Poulter NR, Sanderson JE, Sever PS, Thompson AV. Nifedipine versus propranolol as second line therapy in lowrenin black hypertensives (abstract). Second European Meeting on Hypertension, Milan (Italy), June 9–12, 1985.

  45. Hollifield JW, Edwards EC. Blood pressure responses to diuretic and verapamil in black and white hypertensives. In:3rd International Interdisciplinary Conference on Hypertension in Blacks, April 21–23, 1988, Baltimore.

  46. Leary WP, Asmal AC. Treatment of hypertension with verapamil.Curr Ther Res 1979;25:747–752.

    Google Scholar 

  47. Moser M, Lunn J, Nash DT, et al. Nitrendipine in the treatment of mild to moderate hypertension.J Cardiovasc Pharmacol 1984;6(Suppl):1085s-1089s.

    Article  Google Scholar 

  48. Olivari MT, Bartorelli C, Polese A, et al. Treatment of hypertension with nifedipine a calcium antagonistic agent.Circulation 1979;59:1056–1062.

    PubMed  CAS  Google Scholar 

  49. Kiowski W, Bertel O, Erne P, et al. Hemodynamic and reflex mechanisms of acute and chronic antihypertensive therapy with the calcium channel blocker nifedipine.Hypertension 1983;5(Suppl I):170–174.

    Google Scholar 

  50. McGregor GA, Rotellar C, Markandu ND, et al. Contrasting effects of nifedipine, captopril and propranolol in normotensive and hypertensive subjects.J Cardiovasc Pharmacol 1982;4(Suppl 3):358s-361s.

    Google Scholar 

  51. Hulthen UL, Bolli P, Amann FW, et al. Enhanced vasodilation in essential hypertension by calcium channel blockade with verapamil.Hypertension 1982;4(Suppl II):II26-II31.

    Google Scholar 

  52. Butel O, Coner D, Radu EW, et al. Nifedipine in hypertensive emergencies.Br Med J 1983;286:19–21.

    Article  Google Scholar 

  53. Hall WD. Pharmacologic therapy of hypertension in blacks. In: Hall WD, Saunders E, Shulamn NB, eds.Hypertension in blacks: Epidemiology, pathophysiology and treatment. Chicago: Year Book Medical Publishers, 1985:182–208.

    Google Scholar 

  54. Buhler FR, Hulthen UL, Kiowski W, Bolli P. Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients.Clin Sci 1982;63: (Suppl):439s-442s.

    Google Scholar 

  55. Nicholson JP, Resnick LM, Laragh JH. The antihypertensive effect of verapamil at extremes of sodium intake.Ann Intern Med 1987;107:329–334.

    PubMed  CAS  Google Scholar 

  56. Erne P, Bolli P, Bertel O, et al. Factors influencing the hypotensive effects of calcium antagonists.Hypertension 1983;5(Suppl II):II97-II102.

    PubMed  CAS  Google Scholar 

  57. Buhler FR, Kiowski W. Age and antihypertensive response to calcium antagonists.J Hypertens 1987;5(Suppl 4):111s-114s.

    Article  Google Scholar 

  58. Esler M, Zweifler A, Randall O, et al. Suppression of sympathetic nervous function in low renin essential hypertension.Lancet 1976;2:115–118.

    Article  PubMed  CAS  Google Scholar 

  59. Bertel O, Buhler FR, Kiowski W, Lutold BE. Decreased beta-adrenoceptor responsiveness as related to age, blood pressure and plasma catecholamines in patients with essential hypertension.

  60. M'Buyamba-Kabangu JR, Lijnen P, Groeseneken D, et al. Racial differences in intracellular concentration and homomembrane fluxes of sodium and potassium in erythrocytes of normal male subjects.J Hypertens 1984;2:647–651.

    Article  PubMed  Google Scholar 

  61. Aderounmu AF, Salako LA. Abnormal cation composition and transport in erythrocytes from hypertensive patients.Eur J Clin Invest 1979;9:369–375.

    Article  PubMed  CAS  Google Scholar 

  62. Cole CH. Erythrocyte membrane sodium transport in patients with treated and untreated essential hypertension.Circulation 1983;68:17–22.

    PubMed  CAS  Google Scholar 

  63. Canessa M, Adragna N, Solomon H, et al. Increased sodium lithium countertransport in red cells of patients with essential hypertension.N Engl J Med 1980;302:772–776.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Department of Internal Medicine, University Hospital of Kinshasa, University of Kinshasa (Unikin), B.P. 14280, Kinshasa 1, Zaire

    J. R. M'Buyamba-Kabangu M.D. & M. Tambwe

Authors
  1. J. R. M'Buyamba-Kabangu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Tambwe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

M'Buyamba-Kabangu, J.R., Tambwe, M. The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks. Cardiovasc Drug Ther 4 (Suppl 2), 389–394 (1990). https://doi.org/10.1007/BF02603182

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02603182

Key Words

Search

Navigation